Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...

Over the past few months, investigative journalist Charles Piller has published—eg, in The Daily Mail, The New York Times, ...

Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

There’s so much to process after an Alzheimer’s diagnosis. Whether it’s you or a loved one who has this disease, you’re ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

A recent trial on gantenerumab showed that the drug could reduce the risk of Alzheimer’s symptoms by 50% in pre-symptomatic ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab (Leqembi) and donanemab (Kisunla) have since received federal government approval and are being ...